Introduction

INTRODUCTION

As the field of antibody engineering and therapeutics has been expanding, so have modalities and targets, venturing both inside and outside of oncology.

In the last year, COVID-19 was also thrown into the mix, creating a global demand for drug development. However, there are still gaps to be filled in technology for antibody-based drug discovery, as well as understanding around novel targets.

In April 2021, Antibody Engineering & Therapeutics conducted a global survey of professionals across the industry, to find out where activities have shifted, and which struggles remain.

This report is based on the 111 responses to the survey, revealing unique insights into the current and future trends in antibody-based therapeutic development.

KEY INSIGHTS

• 42% of respondents say that novel targets for antibodies is the most important area of development to them.
• Antibody drug discovery processes are rated the biggest challenge in antibody engineering and therapeutic R&D.
• 41% of respondents believe that combination antibody mediated immunotherapy is the most exciting emerging trend in antibody engineering and therapeutics.
• 55% of the respondents are carrying out work related to COVID-19.
• 45% of respondents say animal models are the best method for obtaining therapeutic antibodies.